Who Paid My Doc
John Anderson
Foot and Ankle Surgery Grand Rapids, MI Medical Doctor
NPI 1700874294 CMS profile 168470
1111 Leffingwell Ave Ne, Ste 100, Grand Rapids, MI 49525
General payments
$1,277,957
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$52,766
Through program year 2025, John Anderson of Grand Rapids, MI is reported in the CMS Open Payments database as having received $1,277,957 across 358 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $52,766 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 97th percentile of Foot and Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $102,585 | 40 | |
| 2024 | General | $201,458 | 44 | |
| 2023 | General | $206,746 | 65 | |
| 2022 | General | $334,316 | 53 | |
| 2021 | General | $153,883 | 44 | |
| 2020 | General | $94,983 | 37 | |
| 2019 | General | $183,987 | 75 |
Beside peers
- John Anderson
- Foot and Ankle Surgery median
- Middle half of Foot and Ankle Surgery
- National median
In program year 2025, general payments to John Anderson were reported at $102,585. Among 650 Foot and Ankle Surgery profiles paid that year, the median was $1,183 and the middle half received between $267 and $6,309.
Show as a table
| Year | John Anderson | Foot and Ankle Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $183,987 | $1,327 | $279–$5,421 | $163 |
| 2020 | $94,983 | $795 | $121–$3,473 | $114 |
| 2021 | $153,883 | $1,289 | $201–$4,963 | $132 |
| 2022 | $334,316 | $1,539 | $270–$6,067 | $149 |
| 2023 | $206,746 | $1,117 | $257–$5,264 | $160 |
| 2024 | $201,458 | $1,064 | $235–$4,944 | $164 |
| 2025 | $102,585 | $1,183 | $267–$6,309 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 8 drugsPart D claims
412
Drug cost
$2,112
Branded share of claims
42.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 132 | $785 | |
| Cyclobenzaprine Hcl | Generic | 136 | $431 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 44 | $361 | |
| Cephalexin | Generic | 31 | $195 | |
| Gabapentin | Generic | 12 | $143 | |
| Celecoxib | Generic | 13 | $132 | |
| Tramadol Hcl | Generic | 15 | $40 | |
| Amoxicillin | Generic | 29 | $26 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 73 billing codesPaid by Medicare
$76,604
Medicare patients
204
Services billed
2,158
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 75% | |
| High blood pressure | 64% | |
| Depression | 27% | |
| Chronic kidney disease | 24% | |
| Diabetes | 22% | |
| Ischemic heart disease | 21% | |
| Atrial fibrillation | 16% | |
| Osteoporosis | 15% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, methylprednisolone acetate, 1 mg J1010 | Office | 13 | 1,120 | $116 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
358 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Foot and Ankle Surgery in Michigan
Christopher Zingas
Foot and Ankle Surgery · Saint Clair Shores, MI
John Maskill
Foot and Ankle Surgery · Grand Rapids, MI
Michael Swords
Foot and Ankle Surgery · Lansing, MI
Arthur Manoli
Foot and Ankle Surgery · Pontiac, MI
Erik Eller
Foot and Ankle Surgery · Novi, MI
Garett Pangrazzi
Foot and Ankle Surgery · Grand Rapids, MI
Related records
Foot and Ankle Surgery in Michigan
Practitioners in the same specialty and state, ranked by reported value.
All Foot and Ankle Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Michigan
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.